If results continue developing at 1%, maintaining that concentration makes sense until improvements naturally level off
The consistent theme is restraint: hold the per-dose amount steady, use frequency and cycle structure as the adjustable variables, and build in breaks
Each fragment undergoes UPLC purity verification after synthesis, enabling real-time monitoring and timely correction of key processes to ensure that intermediate quality meets preset standards
Ultimately, treatment decisions should be individualized based on a patients overall health, risks, and goals
Read more: #ClinicalTrials #AtaiBeckley #BreakthroughsInMentalHealth #TRD To view or add a comment, sign in A successful EndofPhase 2 meeting is one of the most important moments in any clinical program, and Im pleased to share that the FDA indicated support for our proposed Phase 3 pivotal program for BPL003 in treatmentresistant depression